Related Experiment Video
Updated: Jan 10, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
HPD is an m6A Methyltransferase that Protects Colorectal Cancer Cells from Ferroptotic Cell Death by m6A Methylating
Jiyan Wang1, Xintong Dai1, Huanle Liu1
1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, 300350, China.
Abstract:
N6-methyladenosine (m6A) is a dynamic RNA modification, which is added by the METTL3-METTL14 methyltransferase complex or METTL16. Unexpectedly, the tyrosine metabolism enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD) is discovered as a methyltransferase responsible for m6A modification. Unlike METTL3, which requires the assistance of METTL14 to form a complex and exert methyltransferase activity. Interestingly, it is revealed that HPD has a catalytic domain (CMI) like METTL3. Moreover, HPD recruits the universal cofactor S-adenosylmethionine (SAM) to the substrate binding center as a methyl group donor. In particular, it is demonstrated that HPD regulates colorectal cancer ferroptosis by methylating SLC7A11/GPX4 through a moonlighting function. These findings uncover the moonlighting function of HPD in m6A-mediated ferroptosis and underscore the potential to target the m6A methyltransferase activity of HPD for cancer treatment.
Related Concept Videos
Abnormal Proliferation
Hedgehog Signaling Pathway
Export of Misfolded Proteins out of the ER
Negative Regulator Molecules

